Valuation: Sunho Biologics, Inc.

Market Cap 906M 1.07B 136M 121M 112M 102M 190M 12.9B 193M 1.35B 534M 6.76B 510M 499M 21.3B P/E 2023 *
-
P/E 2024 -5.67x
Enterprise Value 490M 576M 73.47M 65.61M 60.61M 54.93M 103M 6.97B 104M 729M 289M 3.65B 276M 270M 11.52B EV / Sales 2023 *
-
EV / Sales 2024 3,059x
Free-Float
32.45%
Yield 2023 *
-
Yield 2024 -
Current year 5.49
Extreme 5.49
8
1 year 5.49
Extreme 5.49
8.08
3 years 3
Extreme 3
15.42
5 years 3
Extreme 3
15.42
10 years 3
Extreme 3
15.42
Manager TitleAgeSince
Chief Executive Officer 44 23/01/2026
Director of Finance/CFO 47 22/07/2023
Corporate Secretary 35 22/07/2023
Director TitleAgeSince
Chairman 53 22/07/2023
Director/Board Member 44 21/07/2023
Director/Board Member 52 22/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-19.52% - 124M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.25%+0.28%+42.87%+118.47% 38.2B
Weighted average by Cap. +0.38%+0.55%+48.15%+122.11%

Financials

2023 2024
Net sales 17.53M 20.61M 2.63M 2.35M 2.17M 1.97M 3.68M 250M 3.74M 26.1M 10.33M 131M 9.87M 9.66M 412M 38K 44.68K 5.7K 5.09K 4.7K 4.26K 7.97K 541K 8.1K 56.56K 22.39K 283K 21.38K 20.93K 893K
Net income -133M -156M -19.89M -17.77M -16.41M -14.87M -27.83M -1.89B -28.29M -197M -78.19M -989M -74.66M -73.07M -3.12B -79.96M -94.02M -11.99M -10.71M -9.89M -8.96M -16.77M -1.14B -17.05M -119M -47.12M -596M -44.99M -44.03M -1.88B
Net Debt -201M -236M -30.13M -26.91M -24.86M -22.53M -42.15M -2.86B -42.84M -299M -118M -1.5B -113M -111M -4.73B -416M -489M -62.38M -55.71M -51.46M -46.64M -87.25M -5.92B -88.69M -619M -245M -3.1B -234M -229M -9.78B
Projected Income Statement - Annual - Sunho Biologics, Inc.
Logo Sunho Biologics, Inc.
Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.
Employees
-
  1. Stock Market
  2. Stocks
  3. 2898 Stock